Clinical experience with gefitinib: An update

Federico Cappuzzo, Giovanna Finocchiaro, Giulio Metro, Stefania Bartolini, Elisabetta Magrini, Alessandra Cancellieri, Rocco Trisolini, Luciano Castaldini, Giovanni Tallini, Lucio Crino

Research output: Contribution to journalArticlepeer-review


Gefitinib is an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that blocks signal transduction pathways involved in cell proliferation. This drug demonstrated impressive and durable responses in patients with heavily pretreated non-small cell lung cancer (NSCLC). In two large phase II trials, responses were observed in 9-19% of unselected patients, along with symptom improvement and benefit in quality of life. Biological mechanisms underlying TKI sensitivity have recently been discovered. There is evidence that specific EGFR gene mutations and/or amplification confer a particularly sensitive phenotype, especially in individuals with tumors demonstrating activation of the anti-apoptotic protein Akt. However, in all so far conducted clinical trials, no patient selection has been made, providing a logical explanation for the negative results observed in large phase III studies. In the present review, we will summarize the results observed in clinical trials with gefitinib. We will present results obtained in NSCLC and in other solid tumor, focusing on biological and clinical markers predicting drug sensitivity.

Original languageEnglish
Pages (from-to)31-45
Number of pages15
JournalCritical Reviews in Oncology/Hematology
Issue number1
Publication statusPublished - Apr 2006


  • EGFR
  • Gefitinib
  • Non-small cell lung cancer
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Clinical experience with gefitinib: An update'. Together they form a unique fingerprint.

Cite this